other material
confidence high
sentiment positive
materiality 0.55
Cocrystal Pharma reports favorable Phase 1 safety/tolerability for oral antiviral CDI-988 at 800 mg for 10 days
Cocrystal Pharma, Inc.
- Phase 1 MAD study shows CDI-988 well-tolerated up to 800 mg/day for 10 days; new cohort at 1,200 mg for 5 days planned.
- Pan-viral inhibitor targets norovirus and coronaviruses; no approved antivirals for norovirus exist.
- Company plans to start human challenge study in norovirus-infected subjects later in 2025.
- Norovirus outbreaks surge in U.S.; CDC estimates 21 million annual U.S. cases and $10.6B economic burden.